$400.69
0.50% day before yesterday
Nasdaq, Dec 24, 07:00 pm CET
ISIN
US02043Q1076
Symbol
ALNY

Alnylam Pharmaceuticals, Inc Stock price

$400.69
-33.54 7.72% 1M
+75.69 23.29% 6M
+165.38 70.28% YTD
+157.44 64.72% 1Y
+162.79 68.43% 3Y
+263.13 191.28% 5Y
+310.01 341.87% 10Y
+387.20 2,870.27% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+1.99 0.50%
ISIN
US02043Q1076
Symbol
ALNY
Industry

New AI Insights on Alnylam Pharmaceuticals, Inc Insights AI Insights on Alnylam Pharmaceuticals, Inc

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Key metrics

Basic
Market capitalization
$52.9b
Enterprise Value
$52.7b
Net debt
positive
Cash
$2.7b
Shares outstanding
131.8m
Valuation (TTM | estimate)
P/E
1,292.5 | 214.0
P/S
16.5 | 13.8
EV/Sales
16.4 | 13.8
EV/FCF
238.2
P/B
226.3
Financial Health
Equity Ratio
1.6%
Return on Equity
-414.6%
ROCE
8.0%
ROIC
-19.1%
Debt/Equity
10.7
Financials (TTM | estimate)
Revenue
$3.2b | $3.8b
EBITDA
$321.0m | $561.7m
EBIT
$264.7m | $500.5m
Net Income
$43.6m | $246.7m
Free Cash Flow
$221.4m
Growth (TTM | estimate)
Revenue
53.2% | 70.0%
EBITDA
342.9% | 567.3%
EBIT
240.7% | 382.9%
Net Income
113.1% | 188.7%
Free Cash Flow
1,282.6%
Margin (TTM | estimate)
Gross
83.9%
EBITDA
10.0% | 14.7%
EBIT
8.3%
Net
1.4% | 6.5%
Free Cash Flow
6.9%
More
EPS
$0.3
FCF per Share
$1.7
Short interest
4.2%
Employees
2k
Rev per Employee
$1.0m
Show more

Is Alnylam Pharmaceuticals, Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Alnylam Pharmaceuticals, Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

37 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:

27x Buy
73%
10x Hold
27%

Analyst Opinions

37 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:

Buy
73%
Hold
27%

Financial data from Alnylam Pharmaceuticals, Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
3,210 3,210
53% 53%
100%
- Direct Costs 517 517
69% 69%
16%
2,693 2,693
51% 51%
84%
- Selling and Administrative Expenses 1,181 1,181
34% 34%
37%
- Research and Development Expense 1,248 1,248
14% 14%
39%
321 321
343% 343%
10%
- Depreciation and Amortization 56 56
1% 1%
2%
EBIT (Operating Income) EBIT 265 265
241% 241%
8%
Net Profit 44 44
113% 113%
1%

In millions USD.

Don't miss a Thing! We will send you all news about Alnylam Pharmaceuticals, Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alnylam Pharmaceuticals, Inc Stock News

Neutral
Business Wire
9 days ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is preparing to invest $250 million to advance what is poised to become the industry's first fully dedicated, proprietary, siRNA enzymatic-ligation manufa...
Neutral
Market Watch
13 days ago
Six companies will join the Nasdaq-100 later this month — but not Walmart, which switched its listing away from the New York Stock Exchange too late to qualify for a spot in the tech-heavy index.
Positive
Market Watch
15 days ago
The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull market.
More Alnylam Pharmaceuticals, Inc News

Company Profile

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Head office United States
CEO Yvonne Greenstreet
Employees 2,230
Founded 2002
Website www.alnylam.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today